Immunizations in Pregnancy
LEANNE ZAKRZEWSKI, MD, and DENISE SUR, MD
University of California, Los Angeles, David Geffen School of Medicine, Santa Monica, California

Vaccinations are an important topic to address with pregnant women for maternal and neonatal health reasons, and pregnancy provides a unique time during which physicians have close, regular contact with the patient. Inactivated vaccines can be given before, during, and after pregnancy. Based strictly on theoretical concerns, live vaccines preferably should be given at least one month before pregnancy and avoided during pregnancy. Based on current data, the MMR vaccine should be provided between 27 and 36 weeks of gestation. This timing recommendation is based on the maternal immune response, which peaks two weeks after administration. If not given during pregnancy (and for the protection of the newborn), the Tdap vaccine should be administered immediately postpartum in any woman who has not previously received it. If Tdap vaccination history cannot be confirmed through written records, the patient should be considered unvaccinated and should receive a Tdap vaccine.

Immunizations to Avoid

The hepatitis B vaccine has not been shown to cause any harm to the developing fetus. Based on current data, the hepatitis B vaccine should be provided to any pregnant woman at higher risk of exposure to hepatitis B (e.g., multiple sex partners, recent injection drug use). Adequate safety data do not exist for the hepatitis A vaccine, but the theoretical risks are low because it is produced from an inactivated virus. Women who are thought to be at high risk of exposure to hepatitis A should be considered for vaccination during pregnancy (e.g., travel to endemic countries, chronic liver disease).

Immunizations to Consider

The hepatitis B vaccine should be provided to any pregnant woman at higher risk of exposure to hepatitis B (e.g., multiple sex partners, recent injection drug use). Adequate safety data do not exist for the hepatitis A vaccine, but the theoretical risks are low because it is produced from an inactivated virus. Women who are thought to be at high risk of exposure to hepatitis A should be considered for vaccination during pregnancy (e.g., travel to endemic countries, chronic liver disease).

Immunizations to Target

PREGNANCY

Influenza infection increases the risk of serious complications in pregnant women and their newborns, as well as the risk of premature labor and delivery. A recent randomized study of 340 women also showed a higher incidence of small-for-gestational-age infants when the mother had not been vaccinated. Because the influenza vaccine is safe in pregnancy, vaccinating all pregnant women during any trimester should be a priority to minimize these risks. In a Centers for Disease Control and Prevention (CDC) study analyzing data from the 2009 to 2010 Pregnancy Risk Assessment Monitoring System, influenza vaccination coverage during pregnancy was considerably higher when the physician recommended or offered it (median of 53.1%) compared with when the physician did not (median of 14.4%).

Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine should be provided during each pregnancy, preferably between 27 and 36 weeks of gestation. This timing recommendation is based on the maternal immune response, which peaks two weeks after administration. If not given during pregnancy (and for the protection of the newborn), the Tdap vaccine should be administered immediately postpartum in any woman who has not previously received it. If Tdap vaccination history cannot be confirmed through written records, the patient should be considered unvaccinated and should receive a Tdap vaccine.

Rubella infection is likely to cause fetal infection, which can result in miscarriage, fetal demise, and serious birth defects (e.g., cataracts, heart disease, deafness, intellectual disability). Therefore, it is key to determine a patient’s immunity and, if indicated, provide vaccination before pregnancy. Rubella vaccination is typically provided with the measles-mumps-rubella (MMR) vaccine, which is a combination live vaccine.

Although the effects of varicella virus on the fetus are unknown, there are theoretical concerns, and the risk of severe varicella virus infection may be higher in pregnant women. Therefore, vaccinating nonimmune women before pregnancy is recommended.
Registries for reporting inadvertent immunization during pregnancy have been established for the varicella, HPV, and herpes zoster vaccines:

- Merck for the varicella (Varivax), herpes zoster (Zostavax), and quadrivalent HPV (Gardasil) vaccines: 800-986-8999
- GlaxoSmithKline for the bivalent HPV vaccine (Cervarix): 888-452-9622

Address correspondence to Leanne Zakrzewski, MD, at lzakrzewski@mednet.ucla.edu. Reprints are not available from the authors.

Author disclosure: No relevant financial affiliations.

REFERENCES